Overview

A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, multi-center, randomized, open-label study to evaluate the safety, tolerability, and efficacy of Albuferon in subjects with hepatitis C (HEP C) who failed to respond to previous interferon alfa therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Human Genome Sciences Inc.
Treatments:
Interferons
Ribavirin